Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial ViremiaGeorgia D. Tomaras, Barton F. Haynes|Journal of Virology|2008Cited by 624
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Jerald Sadoff et al.|The Lancet|2018Cited by 342
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, Hua-Xin Liao et al.|Science|2015Cited by 202
Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2011Cited by 177
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)Gavin Churchyard, Cecilia Morgan, Elizabeth M. Adams et al.|PLoS ONE|2011Cited by 137